Glenview Trust Co Increases Stock Position in Astrazeneca Plc $AZN

Glenview Trust Co lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 65.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,923 shares of the company’s stock after acquiring an additional 3,130 shares during the quarter. Glenview Trust Co’s holdings in Astrazeneca were worth $1,390,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of AZN. Bank of Montreal Can lifted its stake in shares of Astrazeneca by 344.6% during the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Astrazeneca by 41.8% during the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after buying an additional 1,807,565 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of Astrazeneca by 11,190.9% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after buying an additional 1,790,874 shares in the last quarter. Raymond James Financial Inc. lifted its stake in shares of Astrazeneca by 64.8% during the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after buying an additional 1,487,662 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Performance

Astrazeneca stock opened at $187.24 on Tuesday. The firm’s 50 day simple moving average is $191.60 and its 200 day simple moving average is $183.22. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $290.39 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 1.54 and a beta of 0.26. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, analysts expect that Astrazeneca Plc will post 9.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on AZN shares. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Barclays upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings started coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Finally, UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.